Conception of myeloperoxidase inhibitors derived from flufenamic acid by computational docking and structure modification

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 4, 2008, Pages 1702-1720

  Van Antwerpen, Pierre ^a   Prévost, Martine ^a   Zouaoui Boudjeltia, Karim ^a   Babar, Sajida ^a   Legssyer, I ^a   Moreau, Patrick ^a   Moguilevsky, Nicole ^b   Vanhaeverbeek, Michel ^a   Ducobu, Jean ^c   Nève, Jean ^a   Dufrasne, François ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b UNIVERSITY OF NAMUR   (Belgium)

^c Centre Hospitalier Universitaire de Tivoli   (Belgium)

Author keywords

Chronic inflammatory diseases; Flufenamic acid; LDL; Molecular docking; Myeloperoxidase

Indexed keywords

FLUFENAMIC ACID; LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE; TAURINE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; LIPID OXIDATION; PROTEIN DETERMINATION; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

COMPUTER SIMULATION; ENZYME INHIBITORS; FLUFENAMIC ACID; HUMANS; LIPOPROTEINS, LDL; MOLECULAR STRUCTURE; PEROXIDASE; PROTEIN BINDING;

EID: 38949096400     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.11.025     Document Type: Article

References (48)

1. Klebanoff S.J. J. Leukoc. Biol. 77 (2005) 598
2. Nurcombe H.L., Bucknall R.C., and Edwards S.W. Ann. Rheum. Dis. 50 (1991) 237
3. Malle E., Waeg G., Schreiber R., Gröne E.F., Sattler W., and Gröne H.-J. Eur. J. Biochem. 267 (2000) 4495
4. Choi D.-K., Pennathur S., Perier C., Tieu K., Teismann P., Wu D.-C., Jackson-Levis V., Vila M., Vonsattel J.P., and Heinecke J.W. J. Neurosci. 25 (2005) 6594
5. Carr A.C., Decker E.A., Park Y., and Frei B. Free Radic. Biol. Med. 31 (2001) 62
6. Moguilevsky N., Zouaoui Boudjeltia K., Babar S., Delrée P., Legssyer I., Carpentier Y., Vanhaeverbeek M., and Ducobu J. Biochem. Biophys. Res. Commun. 323 (2004) 1223
7. Zouaoui Boudjeltia K., Legssyer I., Van Antwerpen P., Kisoka R.L., Babar S., Moguilevsky N., Delree P., Ducobu J., Remacle C., Vanhaeverbeek M., and Brohee D. Biochem. Cell Biol. 84 (2006) 805
8. Zheng L., Settle M., Brubaker G., Schmitt D., Hazen S.L., Smith J.D., and Kinter M. J. Biol. Chem. 280 (2005) 38
9. Soyer Z., Bas M., Pabuccuoglu A., and Pabuccuoglu V. Arch. Pharm. 338 (2005) 405
10. Kettle, A.; Tiden, A.-K. PCT Int. Pat. 2005037835; 2005.
11. Nève J., Parij N., and Moguilevsky N. Eur. J. Pharmacol. 417 (2001) 37
12. Van Antwerpen P., Dufrasne F., Lequeux M., Zouaoui Boudjeltia K., Legssyer I., Babar S., Moreau P., Moguilevsky N., Vanhaeverbeek M., Ducobu J., and Neve J. Eur. J. Pharmacol. 570 (2007) 235
13. Blair-Johnson M., Fiedler T., and Fenna R. Biochemistry 40 (2001) 13990
14. Davey C.A., and Fenna R.E. Biochemistry 35 (1996) 10967
15. Hardy L.W., and Malikayil A. Curr. Drug Discov. 3 (2003) 15
16. Van Antwerpen P., Zouaoui Boudjeltia K., Babar S., Legssyer I., Moreau P., Moguilevsky N., Vanhaeverbeek M., Ducobu J., and Nève J. Biochem. Biophys. Res. Commun. 337 (2005) 82
17. Friesner R.A., Banks J.L., Murphy R.B., Halgren T.A., Klicic J.J., Mainz D.T., Repasky M.P., Knoll E.H., Shelley M., Perry J.K., Shaw D.E., Francis P., and Shekin P.S. J. Med. Chem. 47 (2004) 1739
18. Poulos T.L., and Kraut J. J. Biol. Chem. 255 (1980) 8199
19. Sadighi J.P., Harris M.C., and Buchwald S.L. Tetrahedron Lett. 39 (1998) 5327
20. Hosangadi B.D., and Dave R.H. Tetrahedron Lett. 37 (1996) 6375
21. Su Q., and Panek J.S. J. Am. Chem. Soc. 126 (2004) 2425
22. Chang J., Guo X., Cheng S., Guo R., Chen R., and Zhao K. Bioorg. Med. Chem. Lett. 14 (2004) 2131
23. Hartwell J.L. Organic Syntheses Vol. 24 (1944), Wiley, New York 22-24
24. Perez-Alvarez M., Raymo F.M., Rowan S.J., Shiraldi D., Fraser Stoddart J., Wang Z.-H., White A.J.P., and Williams D.J. Tetrahedron 57 (2001) 3799
25. Nishimura S. Handbook of Heterogeneous Catalytic Hydrogenation for Organic Synthesis (2001), Wiley, New York 584
26. Carrico D., Ohkanda J., Kendrick H., Yokoyama K., Blaskovitch M.A., Bucher C.J., Buckner F.S., Van Voorhis W.C., Chakrabarti D., Croft S.L., Gelb M.H., Sebti S.M., and Hamilton A.D. Bioorg. Med. Chem. 12 (2004) 6517
27. Marquez L.A., Huang J.T., and Dunford H.B. Biochemistry 33 (1994) 1447
28. Arnhold J., Furtmüller P.G., and Obinger C. Redox Rep. 8 (2003) 179
29. Furtmüller P.G., Burner U., Jantschko W., Regelsberger G., and Obinger C. FEBS Lett. 484 (2000) 139
30. Kettle A.J., and Winterbourn C.C. Biochem. J. 252 (1988) 529
31. Burner U., Jantschko W., and Obinger C. FEBS Lett. 443 (1999) 290
32. Furtmüller P.G., Obinger C., Huanyu Y., and Dunford H.B. Eur. J. Biochem. 267 (2000) 5858
33. Sadowski J., and Gasteiger J. Chem. Rev. 93 (1993) 2567
34. Eldridge M.D., Murray C.W., Auton T.R., Paolini G.V., and Mee R.P. J. Comput. Aided Mol. Des. 11 (1997) 425
35. von Boltze K.-H., Bäcker U., and Kreisfeld H. Arzneim.-Forsch. 32 (1982) 183
36. Williams F.J., Relles H.M., and Manello D.P.E. J. Org. Chem. 42 (1977) 3419
37. Burkartsmaier A., and Mutschler E. Arch. Pharm. 311 (1978) 161
38. Superimposed with solvent signal.
39. Signal for C5′ overlapped by another one between 126 and 130 ppm.
40. Since this reaction was strongly exothermic, it is recommended to carefuly follow the described procedure.
41. C-F impossible to determine because of superimposed signals.
42. Beers R.J., and Sizer I.W. J. Biol. Chem. 195 (1952) 133
43. Gressier B., Lebegue N., Brunet C., Luyckx M., Dine T., Cazin M., and Cazin J.C. Pharm. World Sci. 3 (1995) 76
44. Ching T.L., De Jong J., and Bast A. Anal. Biochem. 218 (1994) 377
45. Moguilevsky N., Garcia-Quintana L., Jacquet A., Tournay C., Fabry L., Pierard L., and Bollen A. Eur. J. Biochem. 197 (1991) 605
46. Hewson W.D., and Hager L.P. J. Biol. Chem. 254 (1979) 3175
47. Havel R.J., Eder H.A., and Bragdom J.H. J. Clin. Invest. 34 (1955) 1345
48. Peterson G.L. Anal. Biochem. 83 (1977) 346